Idogen AB (”Idogen”) announces today that Anders Karlsson has been appointed new CEO for the company. He will take up his new position on August 19, 2019.
Anders Karlsson has a broad experience from a range of pharma and medtech companies, including leading positions at Novartis and Olerup International. Most recently, Anders Karlsson served as CEO of Allenex AB where he managed the merger with CareDx Inc. In his previous positions, he has successfully re-positioned companies and negotiated global cooperation agreements.
”We are very pleased with the recruitment of Anders Karlsson. His combined experience from both the pharma and medtech industries, and renowned management skills, will be of great value for Idogen. Anders has a strong business acumen and has contributed to significant value creation on multiple occasions in his previous roles. The Board of Directors look forward to continue the development of Idogen together with Anders,” comments Idogen’s chairman Agneta Edberg.
”Idogen has ground-breaking development projects within immunology and transplantation, areas which I have worked actively with over the years and where I see tremendous potential. Idogen’s product pipeline can develop into lifesaving treatments for many severely ill patients in the future. With its skilled employees, the company is well positioned for value creation in the coming years and I look forward to lead the company through that journey”, says Anders Karlsson, incoming CEO of Idogen.
For additional information, please contact:
Agneta Edberg, Chairman of the Board, Idogen AB
Tel: +46 (0)70 555 75 18
This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 15 July 2019.
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient’s own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit https://www.idogen.com